DS Healthcare Group Files Patent for Prescription Hair Loss Treatment

Company's first move into pursuing prescription hair loss treatment market

DS Healthcare Group, Inc, a leading developer of personal care products, today announced it has filed a patent application titled, "Compositions and Methods for Treatment of Hair Loss," with the United Stated Patent and Trademark Office.

The patent application addresses DS Healthcare's proprietary formulations that stimulate hair growth and reduce hair loss in men and women through treatments delivered topically.

"We believe there is tremendous unmet demand for an effective prescription grade hair loss treatment.

Although a few other prescription products have been launched for this indication in the past decades, they have either been less effective than users would prefer, or have been coupled been side effects that most users have found to be unacceptable," stated DS Healthcare President and CEO Daniel Khesin. "Having already generated millions of dollars providing over-the-counter shampoos and other topical hair growth products, we know this market and we believe our proprietary prescription-grade formulation holds promise for the millions of people looking to preserve their hair growth."

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical, and nutritional therapies.

It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons.

Its brands include DS Laboratories (www.DSLaboratories.com), Sigma Skin (www.SigmaSkin.com), Polaris Research Laboratories (www.PolarisReserachLabs.com) and The Pure Guild (www.ThePureGuild.com).

Source